Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target lowered by analysts at Stifel Nicolaus from $4.80 to $2.30. They now have a "hold" rating on the stock.
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress [Yahoo! Finance]
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress